Aurinia Pharmaceuticals Inc. Increase (Decrease) in Contract with Customer, Liability
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Contract with Customer, Liability of $1.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $624.00K, a 22.48% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $1.08M, a 75.10% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$482.00K, a 109.15% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$997.00K, a 185.51% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $3.67M, a 36.64% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $5.79M, a 53.84% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $3.76M, a 23.46% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $3.05M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.71M 10-Q · filed 2026-08-06 | $1.22M derived: sum of 3 quarters · filed 2026-08-06 | $226.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.08M 10-Q · filed 2026-05-07 | $599.00K derived: sum of 2 quarters · filed 2026-05-07 | -$398.00K derived: sum of 3 quarters · filed 2026-05-07 | $407.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.48M derived: sum of 2 quarters · filed 2026-02-26 | -$674.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.67M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$997.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$192.00K derived: sum of 2 quarters · filed 2026-08-06 | $4.15M 10-Q · filed 2025-11-04 | $9.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $805.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.15M 10-Q · filed 2026-08-06 | $10.41M derived: sum of 3 quarters · filed 2026-08-06 | $11.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.34M 10-Q · filed 2026-05-07 | $9.61M derived: sum of 2 quarters · filed 2026-05-07 | $10.78M derived: sum of 3 quarters · filed 2026-05-07 | $10.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.43M derived: sum of 2 quarters · filed 2026-02-26 | $5.79M derived: sum of 3 quarters · filed 2026-02-26 | $5.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $525.00K derived: sum of 2 quarters · filed 2025-11-04 | $522.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$641.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$644.00K 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$3.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $3.76M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $3.05M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |